

May/June  
2020



# INSTAND

Summary of Sample Properties and  
Target Values  
of the Extra EQA Scheme  
Virus Immunology –  
SARS-CoV-2 (Ab)

Prof. Dr. Heinz Zeichhardt

Dr. Martin Kammel

Issued by:

**INSTAND**

Gesellschaft zur Förderung  
der Qualitätssicherung  
in medizinischen Laboratorien e.V.

Düsseldorf/Berlin, Germany, 03.07.2020

# INSTAND EQA schemes in virology

in cooperation with:

Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V. (DVV)

Gesellschaft für Virologie e.V. (GfV)

Deutsche Gesellschaft für Hygiene und Mikrobiologie e.V. (DGHM)

**EQAS Adviser:**

Prof. i.R. Dr. Heinz Zeichhardt  
Professor of Virology  
Charité - University Medicine Berlin

**Correspondence address:**

Prof. Dr. Heinz Zeichhardt  
IQVD GmbH  
Institut für Qualitätssicherung in der Virusdiagnostik  
Potsdamer Chaussee 80, D-14129 Berlin, Germany  
Tel.: +49-(0)30-81054-300; Fax: +49-(0)30-81054-303  
Email: [Heinz.Zeichhardt@iqvd.de](mailto:Heinz.Zeichhardt@iqvd.de)

**Assistant EQAS Adviser:**

Dr. Martin Kammel  
c/o INSTAND e.V.  
Ublerstr. 20, D-40223 Düsseldorf, Germany  
Tel.: +49-(0)30-81054-304; Fax: +49-(0)30-81054-303  
Email: [M.Kammel@iqvd.de](mailto:M.Kammel@iqvd.de)

Carried out by:

---

**INSTAND e.V.**  
**Ublerstr. 20**  
**D-40223 Düsseldorf, Germany**  
**Tel.: +49 (0)211 - 1592 13 0**  
**Fax: +49 (0)211 - 1592 1330**  
**Email: [instand@instand-ev.de](mailto:instand@instand-ev.de)**  
**Internet: [www.instand-ev.de](http://www.instand-ev.de)**

## Extra INSTAND External Quality Assessment Scheme – May/June 2020 Virus Immunology – SARS-CoV-2 (Ab)

Dear colleagues,

You have registered for the Extra INSTAND External Quality Assessment (EQA) Scheme Virus Immunology – SARS-CoV-2 (Ab) of May/June 2020. Today you receive information on the provision of your participation documents and the provision of the *summary of sample properties and target values*.

**Since the EQAS term September 2019, your participation documents are available only online. Paper based documents are not sent by mail anymore.**

### 1. Participation documents

With the "EQAS (RV) Online system", you have direct access to your individual participation documents for the corresponding EQA scheme via the button "Evaluation" after login on the INSTAND website <https://rv-online.instandev.de/>.

For download are available:

- Certificate (button "Certificate Download")
- Certificate, certificate of participation, listing and evaluation of results (button "Evaluation Download")
- **Individual summary of results (button "General overview Download")**  
For comparison, you find your own statement and the results of all EQA scheme participants, differentiated by test manufacturer and test name, in the individual summary of results.  
A detailed report on this EQA scheme follows. You will be informed by email.

### 2. Summary of sample properties and target values

The summary of sample properties and target values is available:

- by email with a link to the document "Summary of sample properties and target values" and
- on the INSTAND homepage under "EQAS Online / Service for EQA tests / EQA area (Virus immunology / Virus genome detection)"  
in English language: <http://www.instand-ev.de/en/eqas-online/service-for-eqa-tests.html> and  
in German language: <http://www.instand-ev.de/ringversuche-online/ringversuche-service.html>.

Please see the following Table 1 for details on sample properties and the expected target values for this Extra EQA scheme May/June 2020.

The reports of all EQA schemes will be released on the INSTAND homepage immediately after completion.

For details please see the INSTAND homepage under

"EQAS Online / Service for EQA tests / EQA area (Virus immunology / Virus genome detection)"  
in English language: <http://www.instand-ev.de/en/eqas-online/service-for-eqa-tests.html> and  
in German language: <http://www.instand-ev.de/ringversuche-online/ringversuche-service.html>.

## ACKNOWLEDGEMENT

We thank our cooperation partners for their outstanding support in the introduction of this EQA scheme:

Prof. Dr. Christian Drosten Dr. Victor M. Corman Dr. Daniela Niemeyer Charité - Universitätsmedizin Berlin, Campus Mitte, Institut für Virologie, Nationales Konsiliarlaboratorium für Coronaviren	Prof. Dr. Dr. André Gessner Universität Regensburg, Institut für Medizinische Mikrobiologie und Hygiene, Bereich Klinische Virologie und Infektionsimmunologie
Prof. Dr. Sandra Ciesek Prof. Dr. Holger F. Rabenau Prof. Dr. Annemarie Berger Universitätsklinikum Frankfurt Institut für Medizinische Virologie	Dr. Benedikt Weißbrich Universität Würzburg, Institut für Virologie und Immunbiologie
Dr. Martin Obermeier Dr. Robert Ehret Medizinisches Infektiologiezentrum Berlin	Dr. Michael Müller Prof. Dr. Ralf Ignatius Dr. Johannes Friesen Heike Kietzmann Medizinisches Versorgungszentrum Labor 28 GmbH
Prof. Dr. Florian Klein Dr. Veronica Di Cristanziano Dr. Sabine Awerkiew Dr. Rolf Kaiser Uniklinik Köln, Institut für Virologie	Prof. Dr. Folker Wenzel Hochschule Furtwangen Fakultät Medical and Life Sciences

Surplus samples of the current Extra EQA scheme May/June 2020 and previous EQA schemes in virus diagnostics are available for test assessment of your virus diagnostics. Please contact INSTAND e.V. for details.

Thank you for your kind cooperation.

Prof. Dr. Heinz Zeichhardt

Dr. Martin Kammel

**Table 1:  
Extra EQA Scheme Virus Immunology – SARS-CoV-2 (Ab) – May/June 2020  
Summary of Sample Properties and Target Values  
Subgroup 4161**

Program	Sub-group	RiliBAEK	Sample	Sample source / sample properties	Analyte	Target value
SARS-CoV-2 (Ab) serum* plasma**	4161	<i>conform to B 2</i>	416001*	serum of a patient with signs of COVID-19, occupational infection acquired in the State of Brandenburg, Germany onset of disease: 29.03.2020 clinical signs: fever for two days, sore throat for four days, distorted sense of smell and taste SARS-CoV-2 PCR: positive, 30.03.2020 blood collected: 27.04.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive positive positive not evaluated <sup>§</sup>
			416002*	negative control serum of a healthy blood donor obtained from the DRK Blutspendedienst Nord-Ost (German Red Cross Blood Donation Service North-East) blood collected: March 2015	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative
			416003*	serum of a patient from North Rhine-Westphalia (Cologne Region) with signs of COVID-19, patient lives in the same household as the patient who donated serum for sample 416010 onset of disease: 14.03.2020 clinical signs: limb pains, fatigue, minor cough, no fever, distorted sense of smell and taste SARS-CoV-2 PCR: positive, 19.03.2020 blood collected: 14.04.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive not evaluated <sup>§</sup> positive not evaluated <sup>§</sup>
			416004**	specificity control plasma of a patient from Bavaria with a past infection with human coronavirus (HCoV) 229E infection with HCoV 229E in February 2020 clinical signs of a respiratory HCoV infection HCoV PCR: positive for HCoV 229E blood collected: 08.05.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative

Non-marked samples derive from independent preparations.

<sup>§</sup> The results of this parameter are not evaluated due to inconsistent results (without disadvantage for the certificate).

**Please note:**

For comparison, you find your own statement and the results of all EQA scheme participants, differentiated by test manufacturer and test name, in the individual summary of results.

A detailed report on this EQA scheme follows. You will be informed by email.

**Table 1 (contd.):  
Extra EQA Scheme Virus Immunology – SARS-CoV-2 (Ab) – May/June 2020  
Summary of Sample Properties and Target Values  
Subgroup 4162**

Program	Sub-group	RiliBAEK	Sample	Sample source / sample properties	Analyte	Target value
SARS-CoV-2 (Ab) serum* plasma**	4162	conform to B 2	416005*	serum of a patient from the State of Brandenburg, Germany, with signs of COVID-19, patient lives in the same household as life partner who was tested SARS-CoV-2 positive by PCR (life partner donated serum for sample 416007) onset of disease: 11.03.2020 clinical signs: fatigue, no fever, loss of sense of smell SARS-CoV-2 PCR: not performed due to lack of test capacity blood collected: 28.04.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive not evaluated <sup>§</sup> not evaluated <sup>§</sup> not evaluated <sup>§</sup>
			416006*	Specificity control serum of a patient from Bavaria with a past infection with the human coronaviruses (HCoV) OC43 and HKU1 infection with HCoV OC43 in 2010 and 2018 infection with HCoV HKU1 in 2015 clinical signs of a respiratory HCoV infection HCoV PCR: positive for HCoV OC43 and HKU1, respectively blood collected: 11.05.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative
			416007*	serum of a patient from the State of Brandenburg, Germany, with signs of COVID-19, patient lives in the same household as life partner who donated serum for sample 416005 onset of disease: 12.03.2020 clinical signs: malaise, loss of smell SARS-CoV-2 PCR: positive, 20.03.2020 blood collected: 28.04.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive positive/borderline positive not evaluated <sup>§</sup>
			416008*	negative control serum of a healthy blood donor obtained from the DRK Blutspendedienst Nord-Ost (German Red Cross Blood Donation Service North-East) blood collected: September 2015	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative

Non-marked samples derive from independent preparations.

<sup>§</sup> The results of this parameter are not evaluated due to inconsistent results (without disadvantage for the certificate).

**Please note:**

**For comparison, you find your own statement and the results of all EQA scheme participants, differentiated by test manufacturer and test name, in the individual summary of results.  
A detailed report on this EQA scheme follows. You will be informed by email.**

**Table 1 (contd.):  
Extra EQA Scheme Virus Immunology – SARS-CoV-2 (Ab) – May/June 2020  
Summary of Sample Properties and Target Values  
Subgroup 4163**

Program	Sub-group	RiliBAEK	Sample	Sample source / sample properties	Analyte	Target value
SARS-CoV-2 (Ab) serum* plasma**	4163	conform to B 2	416009*	negative control serum of a healthy blood donor obtained from the DRK Blutspendedienst Nord-Ost (German Red Cross Blood Donation Service North-East) blood collected: October 2015	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative
			416010*	serum of a patient from North Rhine-Westphalia (Cologne Region) with signs of COVID-19, patient lives in the same household as the patient who donated serum for sample 416003 onset of disease: 11.03.2020 clinical signs: fever for two days, limb pains, malaise, distorted sense of smell and taste SARS-CoV-2 PCR: positive, 15.03.2020 blood collected: 04.05.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive positive not evaluated <sup>§</sup> negative
			416011*	Serum of a patient with signs of COVID-19; stay in Switzerland / Canton of Vaud until 14.03.2020 onset of disease: 21.03.2020 clinical signs: minor headache, distorted sense of smell and taste SARS-CoV-2 PCR: after returning to Germany, not performed due to lack of test capacity blood collected: 05.05.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	positive not evaluated <sup>§</sup> positive not evaluated <sup>§</sup>
			416012*	specificity control serum of a patient from Bavaria with a past infection with the human coronavirus (HCoV) HKU1 infection with HCoV HKU1 in February 2020 clinical signs of a respiratory HCoV infection HCoV PCR: positive for HCoV HKU1 blood collected: 11.05.2020	anti-SARS-CoV-2 total anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgA anti-SARS-CoV-2 IgM	negative negative negative negative

Non-marked samples derive from independent preparations.

<sup>§</sup> The results of this parameter are not evaluated due to inconsistent results (without disadvantage for the certificate).

**Please note:**

For comparison, you find your own statement and the results of all EQA scheme participants, differentiated by test manufacturer and test name, in the individual summary of results.

A detailed report on this EQA scheme follows. You will be informed by email.